Achilles Therapeutics PLC Valuation
| ACHLDelisted Stock | USD 1.48 0.01 0.68% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Achilles Therapeutics PLC shows a prevailing Real Value of $1.15 per share. The current price of the firm is $1.48. Our model approximates the value of Achilles Therapeutics PLC from analyzing the firm fundamentals such as return on equity of -0.52, and Current Valuation of (19.21 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Achilles Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Achilles Therapeutics PLC is based on 3 months time horizon. Increasing Achilles Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Achilles stock is determined by what a typical buyer is willing to pay for full or partial control of Achilles Therapeutics PLC. Since Achilles Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Achilles Stock. However, Achilles Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.48 | Real 1.15 | Hype 1.48 |
The intrinsic value of Achilles Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Achilles Therapeutics' stock price.
Estimating the potential upside or downside of Achilles Therapeutics PLC helps investors to forecast how Achilles stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Achilles Therapeutics more accurately as focusing exclusively on Achilles Therapeutics' fundamentals will not take into account other important factors: Achilles Therapeutics Total Value Analysis
Achilles Therapeutics PLC is presently forecasted to have valuation of (19.21 M) with market capitalization of 63.22 M, debt of 4.62 M, and cash on hands of 201.6 M. The negative valuation of Achilles Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Achilles Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(19.21 M) | 63.22 M | 4.62 M | 201.6 M |
Achilles Therapeutics Asset Utilization
One of the ways to look at asset utilization of Achilles is to check how much profit was generated for every dollar of assets it reports. Achilles Therapeutics PLC shows a negative utilization of assets of -0.3 percent, losing $0.003017 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Achilles Therapeutics PLC shows how unproductive it operates for each dollar spent on its assets.Achilles Therapeutics Ownership Allocation
Achilles Therapeutics holds a total of 41.1 Million outstanding shares. The majority of Achilles Therapeutics PLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Achilles Therapeutics PLC to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Achilles Therapeutics. Please pay attention to any change in the institutional holdings of Achilles Therapeutics PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Achilles Therapeutics Profitability Analysis
Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0.About Achilles Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Achilles Therapeutics PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Achilles Therapeutics PLC based exclusively on its fundamental and basic technical indicators. By analyzing Achilles Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Achilles Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Achilles Therapeutics. We calculate exposure to Achilles Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Achilles Therapeutics's related companies.Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company was founded in 2016 and is headquartered in London, the United Kingdom. Achilles Therapeutics is traded on NASDAQ Exchange in the United States.
Achilles Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Achilles Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Achilles Stock
If you are still planning to invest in Achilles Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achilles Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |